{"entity":{"id":"im-seock-ah","kind":"person","name":"Seock-Ah Im","aka":[],"tldr":"Led MONALEESA-7, which proved a CDK4/6 inhibitor extends survival in premenopausal breast cancer, and steers Korea's breast cancer trial network.","summary":"Seock-Ah Im is Professor of Internal Medicine at Seoul National University Hospital, specialising in breast medical oncology. She led MONALEESA-7, the trial that proved the CDK4/6 inhibitor ribociclib with endocrine therapy extends survival in premenopausal women with HR-positive, HER2-negative breast cancer, and steers Korea's breast cancer trial network. She is a principal investigator across the ribociclib, palbociclib and antibody-drug conjugate programmes in breast cancer, including triple-negative disease. Her publications include the MONALEESA-7 report on ribociclib plus endocrine therapy, and her interests are CDK4/6 inhibitors, premenopausal breast cancer and antibody-drug conjugates.","asOf":"2026-09-08","links":[{"label":"Seoul National University Hospital","url":"https://www.snuh.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Im%20SA%5BAuthor%5D%20Seoul%20National%20University%20breast%20cancer"}],"tags":[],"related":[],"cancers":["breast-hr-positive","tnbc"],"sections":[],"technologies":[],"targets":["cdk4-6","estrogen-receptor"],"drugs":["ribociclib","palbociclib"],"companies":[],"institutions":["snuh"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Internal Medicine; breast medical oncology","institutionId":"snuh","specialisms":["Breast cancer","CDK4/6 inhibitors","Premenopausal breast cancer","Antibody-drug conjugates"],"profiles":[{"label":"Seoul National University Hospital","url":"https://www.snuh.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Im%20SA%5BAuthor%5D%20Seoul%20National%20University%20breast%20cancer"}],"papers":[{"title":"Overall survival with ribociclib plus endocrine therapy in breast cancer (MONALEESA-7)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1903765"},{"title":"DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2115022","doi":"10.1056/NEJMoa2115022"},{"title":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2203690","doi":"10.1056/NEJMoa2203690"},{"title":"DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DESTINY-Breast06+trastuzumab+deruxtecan+HER2-low+chemotherapy-naive"},{"title":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2305488","doi":"10.1056/NEJMoa2305488"},{"title":"TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival","journal":"Journal of Clinical Oncology","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TROPION-Breast01+datopotamab+deruxtecan+Bardia"}],"orcid":"0000-0002-5396-6533"},"route":"/people/im-seock-ah/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"target":[{"id":"cdk4-6","kind":"target","name":"CDK4/6","route":"/targets/cdk4-6/"},{"id":"estrogen-receptor","kind":"target","name":"Estrogen receptor (ERα)","route":"/targets/estrogen-receptor/"}],"drug":[{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/"},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/"}],"institution":[{"id":"snuh","kind":"institution","name":"Seoul National University Hospital","route":"/institutions/snuh/"}],"paper":[{"id":"paper-destiny-breast03-nejm-2022","kind":"paper","name":"DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer","route":"/key-papers/paper-destiny-breast03-nejm-2022/"},{"id":"paper-destiny-breast04-nejm-2022","kind":"paper","name":"DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group","route":"/key-papers/paper-destiny-breast04-nejm-2022/"},{"id":"paper-destiny-breast06-nejm-2024","kind":"paper","name":"DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer","route":"/key-papers/paper-destiny-breast06-nejm-2024/"},{"id":"paper-natalee-nejm-2024","kind":"paper","name":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer","route":"/key-papers/paper-natalee-nejm-2024/"},{"id":"paper-tropion-breast01-jco-2024","kind":"paper","name":"TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival","route":"/key-papers/paper-tropion-breast01-jco-2024/"}]}}